CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies

CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies

Caribou Biosciences’ restructuring narrows the biotech’s focus to two off-the-shelf cell therapies for blood cancers, whose key data readouts have been pushed out to the second half of 2025. It’s the CRISPR-editing company’s second cash-saving restructuring in the past year. The post CRISPR Biotech Caribou Trims Pipeline and Cuts 32% of Staff to Focus on Two Cancer Cell Therapies appeared first on MedCity News.

Caribou, in reversal, scraps autoimmune cell therapy and cuts staff

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid to focus resources on a pair of cancer cell therapies.

Caribou cuts pipeline and workforce to focus on lead CAR-T programmes

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.The post Caribou cuts pipeline and workforce to focus on lead CAR-T programmes appeared first on Clinical Trials Arena.

Caribou cuts pipeline and workforce to focus on lead CAR-T programmes - Pharmaceutical Technology

Caribou is scaling back its operations, halting multiple programmes, and cutting staff to focus on two cancer programmes.